Merck plans to submit for EUA for COVID-19 pill, molnupiravir
by Press Release from Outbreak News Today on (#5QBB8)
Merck and Ridgeback Biotherapeutics announced recently that molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19. At the interim analysis, molnupiravir reduced the risk of hospitalization or death [...]
The post Merck plans to submit for EUA for COVID-19 pill, molnupiravir appeared first on Outbreak News Today.